Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum’s first dual switch GoCAR-T
® product candidate that incorporates the company’s iMC activation and CaspaCIDe
® safety switch technologies.
“Initiation of this Phase 1/2 dose escalation clinical trial for BPX-603 denotes an important achievement for Bellicum and represents our second GoCAR-T program to enter the clinic,” stated Rick Fair, President and CEO. “This program may provide further validation of our technology’s ability to enhance both the efficacy and safety of immune cell therapy against solid tumors. We are excited to a